continuing education for pharmacists

Size: px
Start display at page:

Download "continuing education for pharmacists"

Transcription

1 continuing education for pharmacists New Chronic Myeloid Leukemia Drugs: Bosulif, Iclusig, and Synribo Thomas A. Gossel, R.Ph., Ph.D., Professor Emeritus, Ohio Northern University, Ada, Ohio Volume XXXI, No. 7 Dr. Thomas A. Gossel has no relevant financial relationships to disclose. Goal. The goal of this lesson is to provide information on chronic myeloid leukemia and its treatment with three new-molecular entity drugs: bosutinib (Bosulif ), ponatinib (Iclusig ), and omacetaine (Synribo ). Objectives. At the completion of this activity, the participant will be able to: 1. recognize signs and symptoms, and key features of chronic myeloid leukemia (CML) including prevalence; 2. identify the new drugs by generic name, trade name and chemical name when relevant; 3. select the indication(s), pharmacologic action(s) and clinical applications for each drug; 4. identify important therapeutic uses for the drugs and projected benefits over other approved medications for CML; 5. list adverse effects and toicity, significant drug-drug interactions; and 6. demonstrate an understanding of important counseling information to convey to patients and/or their caregivers. Introduction An estimated 5,430 men and women in the United States were diagnosed with chronic myeloid leukemia (CML) in 2012 with a typical-age at diagnosis between 55 and 65 years. CML accounts for about 15 percent of new leukemia cases in adults. It is rare in children. While these figures may not appear overwhelming when aligned with morbidity and mortality data characteristic of more invasive cancers, CML represents a cancer that can be effectively treated and all but eliminated in most patients with early diagnosis and pharmacotherapy. Leukemia Leukemia is a cancer of white blood cells that develops in myeloid tissue (bone marrow). Large numbers of cancerous cells accumulate because they multiply out of control or because they survive much longer than normal cells, or both. With leukemia, the cancerous cells fill the marrow and spill out into the blood. There are several types of leukemia: acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). In acute leukemia, bone marrow cells are immature and are unable to function normally. The number of abnormal cells increases rapidly. In chronic leukemia, cells are more mature and can carry out some of their normal functions, and the number of abnormal cells increases more slowly. Most leukemias arise from cells that normally develop into white blood cells (the word leukemia is derived from a Greek word that means white blood ). Blood cells normally comprise about 40 percent of blood volume and are divided into three major types: erythrocytes (red blood cells; RBCs), leukocytes (white blood cells; WBCs) and platelets (thrombocytes). They are formed in bone marrow by primitive (immature) cells called stem cells that continually divide to produce new cells. There are two types of stem cells: myeloid and lymphoid cells. Some Table 1 New drugs for treatment of chronic myeloid leukemia Generic (Proprietary) Distributor Dosage Form Med Guide* Name Bosutinib (Bosulif) Pfizer Labs 100, 500 mg tabs No Ponatinib (Iclusig) Ariad 15, 45 mg tabs Yes Pharmaceuticals Omacetaine (Synribo) Teva 3.5 mg single- Pharmaceuticals dose vials No *Medication Guide availability information at time of publishing

2 offspring cells remain as stem cells, while others go through a series of maturing stages (precursor or blast cells). Blast cells are new, immature blood cells of any type before forming into mature blood cells. Chronic Myeloid Leukemia CML (sometimes called chronic myelogenous leukemia, chronic granulocytic leukemia or chronic myelocytic leukemia) is a myeloproliferative cancer that develops due to a problem that most likely starts within a single stem cell in the bone marrow, resulting in an acquired genetic mutation. During cell division, some of the DNA from chromosome #9 is transferred to chromosome #22. The resulting abnormal chromosome is termed the Philadelphia (Ph) chromosome (at the molecular level, an oncogene known as Bcr-Abl), and is responsible for CML initiation by causing a clonal epansion of Bcr-Abl-epressing hematopoietic stem cells. An oncogene is genetic material that, when mutated or epressed at high levels, helps turn a normal cell into a cancerous one. These mutant (changed) chromosomes direct the bone marrow to manufacture an enzyme called tyrosine kinase. The resulting Bcr-Abl tyrosine kinase, an oncogenic fusion protein, bypasses the normal cell regulatory processes and leads to an overproduction of myeloid stem cells. These abnormal cells multiply and mature to develop into near-normal white cells, mainly neutrophils, basophils and eosinophils (collectively called granulocytes). Large numbers of these granulocytes that are formed in the bone marrow spill into the blood. The Ph chromosome is not passed from parent to child; thus, CML is not an inherited cancer. CML Progression. CML presents in three stages: chronic phase, accelerated (intermediate) phase, and blast crisis, based on pathology and clinical presentation. The initial (chronic) phase is relatively benign and characterized by welldifferentiated leukemic cells. While the malignant cells have a slight growth advantage, they retain a nearly normal differentiation capacity. In chronic-phase CML, the white blood cell count might be elevated, versus neutrophil and platelet functions that typically remain normal. Within five years of diagnosis, the chronic phase will be followed by progression to the accelerated phase or on to the terminal blast crisis. The accelerated phase shows a peripheral blood pattern of marrow blasts 5 percent, basophils >20 percent and a platelet count of /mm 3, or higher despite adequate therapy. As the abnormal cells accumulate in the bone marrow and blood, it is difficult for cells in the marrow to survive and manufacture enough normal blood cells. The accelerated phase may persist three to 18 months. Approimately 25 percent of patients may transition directly from the chronic phase into blast crisis. In this third phase the condition rapidly worsens and behaves like an acute leukemia. Many immature blast cells develop and fill much of the bone marrow and cause worsening of symptoms. Blast crisis is the remaining challenge in the management of CML. This phase is usually defined by the presence of etramedullary blastic infiltrates of 30 percent leukemic blasts in peripheral blood or marrow. Blast cells are not typically found in circulating blood of healthy individuals. Death is common within three to si months after a patient enters this final phase. Most patients (85 percent) are diagnosed with CML while in the chronic phase. Symptoms, if present, are mild with as many as 45 percent of patients discovered after routine blood tests while still asymptomatic. Approimately 5 percent of patients will have advanced into the accelerated phase and 10 percent into blast crisis when diagnosed. Among patients initially diagnosed in the chronic phase, the accelerated phase is heralded by increased symptoms and greater need for more intensive therapy to control their disease. Symptomatic patients may present with fatigue, weakness, bleeding, sweating, and weight loss. Splenomegaly may induce feelings of early satiety and left upper quadrant pain or mass, and suggests disease acceleration. Leukocytosis, anemia and thrombocytosis are common. Hepatomegaly may occasionally be found. Lymphatic disease and bone marrow malignancies are rare in early CML, but become more common later in the disease and are associated with poor prognosis. Very rarely, CML develops into a condition called myelofibrosis, at which time the bone marrow can no longer make red cells, white cells or platelets because it is replaced by scar tissue (fibrosis). History of CML Therapy. Before the advent of tyrosine kinase inhibitor (TKI) therapy, the median survival time for patients with CML was about four years. Until then, standard treatment for CML consisted of either the alkylating agent busulfan (Busulfe, Myleran) or the ribonucleotide inhibitor hydroyurea (Hydrea). Both busulfan and hydroyurea controlled the hematologic manifestations of CML, but neither modified the clinical course of the cancer. In patients with chronic-phase CML, busulfan and hydroyurea therapy were associated with a median survival of 44 and 56 months, respectively. Interferon-alpha (IFNα; Intron A, Roferon-A) was introduced in the 1980s and improved overall survival. It became the standard of care for CML until the advent of TKI therapy. Treatment with IFNα yielded complete hematologic response in 50 to 80 percent of previously untreated patients with chronic-phase CML. A positive cytogenetic (cell production) response was achieved in 40 to 60 percent of patients, including complete cytogenetic response (defined as no detectable Ph chromosomes in at least 20 bone marrow metaphases) in 5 to 25 percent of patients with chronic-phase CML. The results

3 of numerous randomized clinical trials comparing IFNα and hydroyurea or busulfan showed that IFNα improved survival more than chemotherapeutic agents. Unfortunately, IFNα has minimal activity in CML that has advanced to the accelerated or blastic phase. Moreover, it is also associated with significant adverse effects, including flu-like symptoms, fever, chills, myalgias, fatigue, depression, neuropathy, diarrhea, memory loss, immune-mediated complications and myelosuppression. Tyrosine Kinase Inhibitors. Realization of the critical role that tyrosine kinase plays in the pathogenesis of CML led to a search for specific inhibitors. The most significant advancement in treatment of CML was achieved with introduction in 2001 of imatinib (Gleevec). Imatinib revolutionized the treatment of Philadelphia-positive (Ph+) CML and established targeted Bcr- Abl inhibitors as the standard of care. The drug is a small-molecule TKI that binds to the adenosine triphosphate binding site of the Abl enzyme. This prevents the phosphorylation of a critical residue necessary for substrate binding and kinase activity. Imatinib also inhibits the activity of several other tyrosine kinases. A prospective, randomized, phase III trial (the International Randomized Study of Interferon versus STI571 [IRIS]), was initiated in 2000 to compare single-agent imatinib with IFNα plus low-dose cytarabine (Depocyt, etc.) therapy in treatment-naïve patients with early chronic-phase CML. The outcome of the IRIS trial resulted in a fundamental change in the treatment protocol for CML and established imatinib as its frontline therapy. Imatinib thus became the first TKI to be approved for the treatment of CML and is currently indicated as initial pharmacotherapy for all phases of newly diagnosed CML. At the same time, however, approimately 30 percent of patients will discontinue imatinib therapy because of intolerance, or primary or acquired resistance. In the treatment of CML, failure to meet defined goals for hematologic, cytogenetic, and molecular assessments at specific time points constitutes primary resistance to imatinib. Decreasing response after having achieved these goals is defined as secondary resistance. Initial estimates of primary resistance were 15 to 24 percent at 18 months of follow-up, and for secondary resistance were 7 to 15 percent. More recent estimations, however, are that approimately 40 percent of patients are at a risk of losing the complete cytogenetic response that had been achieved. Following the lead of imatinib, a second generation of TKIs was developed shortly after imatinib failure was identified. An initial important step was the identification of mutations in the tyrosine kinase domain as the most common mechanism of resistance. This was soon followed by development of new agents with higher binding affinity to Bcr-Abl even in the presence of most known mutants. Two of these agents, dasatinib (Sprycel) and nilotinib (Tasigna), have been most etensively studied and have received regulatory approval for use as second-line (i.e., salvage) therapy among patients with resistance or intolerance to imatinib, with more than half (53 to 93 percent) of them achieving a major cytogenetic response. Unfortunately, some patients also develop resistance or intolerance to dasatinib and/or nilotinib. Prior to approval of the three new drugs to be discussed subsequently, treatment options were few for patients previously treated with imatinib, followed by dasatinib and/or nilotinib. Therefore, alternative treatments are needed for patients with chronic-phase CML who have received treatment with and have become resistant to or intolerant of multiple TKIs. The ecellent results obtained with imatinib when used as initial therapy, and availability of effective salvage therapy, redefined the CML treatment algorithm. Nearly all patients are now offered therapy with imatinib at diagnosis, and for those who eperience failure with therapy, a second-generation TKI is indicated. With this approach, the median survival for CML patients will probably eceed 20 years. Among the most intriguing clinical questions remaining in the management of CML is whether patients can eventually discontinue therapy and be cured. The current recommendation is to continue therapy indefinitely. Early attempts at treatment discontinuation among patients with CML suggested that most patients eperienced relapse. The New Drugs Drugs discussed subsequently are new-molecular entity drugs indicated to treat CML (Table 1). The discussion provides a brief introduction to the drugs and is not intended to etend beyond an overview of the topic. The reader is, therefore, encouraged to consult each product s full Prescribing Information leaflet (package insert), Medication Guide when available, and other published reference sources for more detailed information. Bosutinib (Bosulif) Bosulif (BAH-su-lif) was approved for treatment of adult patients with chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib. Mechanism of Action. Bosutinib inhibits the Bcr-Abl kinase (tyrosine kinase) that promotes CML. It also inhibits other kinases. Efficacy. Efficacy was assessed in a single clinical trial that enrolled 546 adult patients with chronic-, accelerated- or blast-phase CML. All subjects had disease that progressed after treatment with imatinib or imatinib followed by dasatinib and/or nilotinib, or who could not tolerate the adverse effects of prior therapy. All patients in the trial received Bosulif. Thirty-three percent of patients

4 Table 2 Eamples of inhibitors and inducers of CYP3A isoenzymes Inhibitors Strong: ritonavir, indinavir, nelfinavir, saquinavir, ketoconazole, boceprevir, telaprevir, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, conivaptan Moderate: fluconazole, darunavir, erythromycin, diltiazem, atazanavir, aprepitant, amprenavir, fosamprevir, crizotinib, imatinib, verapamil, ciprofloacin, grapefruit juice Inducers Strong: rifampin, phenytoin, carbamazepine, St. John s Wort, rifabutin, phenobarbital Moderate: bosentan, nafcillin, efavirenz, modafinil, etravirine with accelerated CML previously treated with at least imatinib had blood counts that returned to normal range (complete hematologic response) and 55 percent achieved normal blood counts without evidence of leukemia (overall hematologic response) within the first 48 weeks of treatment. Meanwhile, 15 percent and 28 percent of patients with blast-phase CML achieved a complete hematologic response and overall hematologic response, respectively. Adverse Reactions. In clinical trials, the most common adverse reactions (incidence >20 percent) were diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, fever and fatigue. Warnings, Precautions and Contraindications. Warnings and precautions are: Gastrointestinal toicity (diarrhea, nausea, vomiting, abdominal pain): monitor and manage as necessary. Withhold, reduce dose, or discontinue Bosulif. Myelosuppression (thrombocytopenia, anemia, neutropenia): monitor blood counts and manage as necessary. Hepatic toicity (elevated liver enzymes and bilirubin): monitor liver enzymes at least monthly for the first three months and as needed. Withhold, reduce dose, or discontinue Bosulif. Fluid retention (pericardial and pleural effusion, pulmonary and peripheral edema): monitor patients and manage using standard of care treatment. Withhold, reduce dose, or discontinue Bosulif. Embryofetal toicity: the drug may cause fetal harm. Females of reproductive potential should avoid becoming pregnant while being treated with Bosulif. The only contraindication is hypersensitivity to Bosulif. Anaphylactic shock occurred in <0.2 percent of patients in clinical trials. Drug Interactions. CYP3A inhibitors and inducers: avoid concurrent use of Bosulif with strong or moderate CYP3A inhibitors and inducers (Table 2). Proton pump inhibitors: may decrease bosutinib drug levels. Consider short-acting antacids or H2-antagonists in place of proton pump inhibitors, with dosing separated by more than two hours. Dosing. Daily doses of 500 mg orally should be taken with food. Continue treatment with Bosulif until disease progression or patient intolerance. If a dose is missed beyond 12 hours, the patient should skip the missed dose and take the usual prescribed dose on the following day. Dose escalation to 600 mg daily can be considered in patients who do not reach complete hematologic response by Week 8 or complete cytogenetic response by Week 12, and who do not have significant adverse reactions. Starting doses should be reduced to 200 mg daily in case of hepatic impairment, and 300 mg daily for renal impairment. Patient Counseling Information. Specific points for counseling as listed in the Prescribing Information leaflet are summarized in Table 3. Ponatinib (Iclusig) Iclusig (eye-clue-sig) received FDA approval for treatment of adult patients with chronic-phase, accelerated phase and blast-crisis CML that is resistant or intolerant to prior TKI therapy or Ph+ ALL that is resistant or intolerant to prior TKI therapy. These indications are based on response rate. There are no studies verifying improvement in disease-related symptoms or increased survival with the drug. Mechanism of Action. Ponatinib is a TKI and inhibitor of other kinases. Efficacy. Efficacy was evaluated in a single clinical trial of 449 patients with various phases of CML and Ph+ ALL. All patients received Iclusig. Effectiveness was demonstrated by a reduction in the percentage of cells epressing the Ph chromosome genetic mutation, a major cytogenetic response (MCyR). Fifty-four percent of all patients and 70 percent of patients with the T3151 mutation achieved MCyR. The median duration of MCyR had not been reached at the time of approval. In accelerated- and blast-crisis CML and Ph+ ALL, the drug s effectiveness was determined by the number of patients who eperienced a normalization of white blood cell counts or had no evidence of leukemia (major hematologic response or MaHR). Results showed: 52 percent of patients with accelerated-phase CML eperienced MaHR for a median duration of 9.5 months; 31 percent of patients with blast-crisis CML achieved MaHR for a median duration of 4.7 months; 41 percent of patients with Ph+ ALL achieved MaHR for a median duration of 3.2 months. Adverse Reactions. The most common non-hematologic adverse reactions ( 20 percent) were hypertension, rash, abdominal pain, fatigue, headache, dry skin, constipation, joint pain, nausea and fever. Hematologic adverse reactions included thrombocytopenia, anemia, neutropenia, lymphopenia and leukopenia.

5 Warnings, Precautions and Contraindications. Warnings and precautions are: Congestive heart failure: monitor patients for signs or symptoms of congestive heart failure and treat as clinically indicated. Hypertension (including confusion, headache, chest pain, shortness of breath, and hypertensive crisis): monitor for high blood pressure and treat as clinically indicated. Pancreatitis: monitor serum lipase monthly; interrupt or discontinue Iclusig. Hemorrhage: interrupt Iclusig for serious or severe hemorrhage. Fluid retention: monitor for fluid retention; interrupt, reduce, or discontinue Iclusig. Cardiac arrhythmias (especially bradyarrhythmias): monitor for symptoms of arrhythmias. Myelosuppression: thrombocytopenia, neutropenia, and anemia may require dose interruption or reduction. Monitor complete blood counts every two weeks for three months and then monthly and as clinically indicated. Interrupt Iclusig for absolute neutrophil count <1000/mm 3 or thrombocytopenia <50,000/mm 3. Tumor lysis syndrome: ensure adequate hydration and correct high uric acid levels prior to initiating therapy with Iclusig Compromised wound healing and gastrointestinal perforation: interrupt therapy for at least one week prior to major surgical procedures. Embryofetal toicity: can cause harm. Advise women of potential risk to a fetus. A Boed Warning advises on the risk of arterial thrombosis and hepatotoicity. There are no contraindications listed for Iclusig. Drug Interactions. Strong CYP3A inhibitors (Table 2): reduce Iclusig dose if co-administration cannot be avoided. Dosing. The recommended dose and schedule is 45 mg given once daily, with or without food. Table 3 Patient counseling information* Tablets should be swallowed whole. Continue treatment as long as there is no evidence of disease progression or unacceptable toicity. Modify or interrupt dosing for hematologic and non-hematologic toicity. Patient Counseling Information. An FDA-approved Medication Guide must be dispensed with Iclusig. Specific points for counseling as listed in the Prescribing Information leaflet are summarized in Table 3. Bosulif Iclusig Synribo Alopecia Bleeding, hemorrhage Compromised wound healing Congestive heart failure, cardiac arrhythmias Dosing, administration Drug interactions Fatigue Fluid retention Gastrointestinal problems Hyperglycemia Hypertension Lactose content Liver problems Low blood cell counts, myelosuppression Other adverse reactions Pancreatitis Pregnancy, breastfeeding Rash Thrombosis, thromboembolism *Specific counseling points in each product s Prescribing Information leaflet (package insert). These are minimum counseling points. Additional information may be included as deemed appropriate. Omacetaine (Synribo) Homoharringtonine (HHT) is a natural alkaloid obtained from the evergreen tree Cephalotaus harringtonia, which is native to China. Its antileukemic activity was first demonstrated in China in the 1970s, and studies in the United States confirmed its usefulness in CML. At one point, HHT was considered the most effective drug treatment for this disease after failure of IFNα; however, the clinical development of HHT in CML came to a halt with introduction of imatinib. Investigation continued, however. Omacetaine is a semisynthetic form of HHT, and its activity in imatinib-resistant CML has established this agent for the second time as a valuable option in management of CML. Synribo (sin-ribo) is FDA approved for treatment of adult patients with chronic- or accelerated-phase CML with resistance and/or intolerance to two or more TKIs. This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with the drug. Mechanism of Action. The mechanism of action of omacetaine has not been fully elucidated but includes inhibition of protein synthesis, and is independent of direct Bcr-Abl binding. Its mechanism differs from TKIs. In vitro, the drug reduces protein levels of the Bcr-Abl oncoprotein.

6 Efficacy. Efficacy was evaluated using a combined cohort of patients whose cancer progressed after previous treatment with two or more TKIs. All participants were treated with Synribo. Its efficacy in chronic-phase CML was demonstrated by a reduction in the percentage of cells epressing the Ph+ mutation. Fourteen out of 76 patients achieved a reduction in an average time of 3.5 months. The median length of the reduction was 12.5 months. In accelerated-phase CML, Synribo s effectiveness was determined by the number of patients who eperienced normalization in white blood cell counts or had no evidence of leukemia (major hematologic response; MaHR). Results showed five out of 35 patients (14.3 percent) achieved MaHR in an average time of 2.3 months. The median duration of MaHR in these patients was 4.7 months. Adverse Reactions. In chronic- and accelerated-phase CML, the most common adverse reactions (frequency 20 percent) were thrombocytopenia, anemia, neutropenia, diarrhea, nausea, fatigue, weakness, injection site reactions, fever, infection and lymphopenia. Warnings, Precautions and Contraindications. Warnings and precautions are: Myelosuppression: severe and fatal thrombocytopenia, neutropenia and anemia. Monitor hematologic parameters frequently. Bleeding: severe thrombocytopenia and increased risk of hemorrhage. Fatal cerebral hemorrhage and severe, non-fatal gastrointestinal hemorrhage. Hyperglycemia: glucose intolerance and hyperglycemia including hyperosmolar non-ketotic hyperglycemia. Embryofetal toicity: can cause fetal harm. Advise females of reproductive potential to avoid pregnancy. There are no contraindications listed for Synribo. Drug Interactions. Omacetaine is not a substrate of CYP450 enzymes or P-glycoprotein in vitro. Based on the findings from in vitro studies, no clinical drug interaction trials were warranted. Preparation and Administration Precautions. Synribo should be reconstituted and administered in a healthcare facility. The drug is an antineoplastic product. Follow special handling and disposal procedures. Avoid contact with the skin. If Synribo comes into contact with skin, immediately and thoroughly wash affected area with soap and water. Dosing. Starting dose for induction is 1.25 mg/m 2 subcutaneously twice daily for 14 consecutive days every 28 days. Repeat cycles every 28 days until hematologic response is seen. For maintenance, administer 1.25 mg/m 2 twice daily for seven consecutive days every 28 days. Treatment should be continued as long as patients are benefitting from therapy. Patient Counseling Information. Specific points for counseling as listed in the Prescribing Information leaflet are summarized in Table 3. Overview and Summary Evolution of understanding the pathophysiology and management of CML has been rapid and immense during the past 50 years. Medical science has advanced from identifying a common cytogenetic abnormality to translating this finding into treatment strategies that have altered the natural history of the disease. With improved treatment options available, CML outcomes may continue to be improved. The author, the Ohio Pharmacists Foundation and the Ohio Pharmacists Association disclaim any liability to you or your patients resulting from reliance solely upon the information contained herein. Bibliography for additional reading and inquiry is available upon request. This lesson is a knowledge-based CE activity and is targeted to pharmacists in all practice settings. Program H01-P Release date: Epiration date: CE Hours: 1.5 (0.15 CEU) The Ohio Pharmacists Foundation Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

7 continuing education quiz New Chronic Myeloid Leukemia Drugs: Bosulif, Iclusig, and Synribo 1. In 2012, the typical age at CML diagnosis was between: a. 35 and 45. c. 55 and 65. b. 45 and 55. d. 65 and All of the following are correct about CML EXCEPT: a. it is a myeloproliferative cancer. b. it is also called chronic granulocytic leukemia. c. some DNA is transferred from chromosome #22 to #9. d. the chronic phase of CML is relatively benign. 3. The Philadelphia chromosome directs bone marrow to manufacture which of the following enzymes? a. Tyrosine kinase c. Threonine kinase b. Thymidine kinase d. Tryptophan kinase 4. Most patients with CML are diagnosed at which of the following levels? a. Acute phase c. Accelerated phase b. Chronic phase d. Blast crisis 5. Historically, standard treatment of CML consisted of which of the following ribonucleotide inhibitor drugs? a. Hydroyurea c. Interferon-alpha b. Busulfan d. Methotreate 6. Adverse effects associated with interferon-alpha include all of the following EXCEPT: a. depression. c. myelosuppression. b. fever. d. splenomegaly. Completely fill in the lettered bo corresponding to your answer. 1. [a] [b] [c] [d] 6. [a] [b] [c] [d] 11. [a] [b] [c] [d] 2. [a] [b] [c] [d] 7. [a] [b] [c] [d] 12. [a] [b] [c] [d] 3. [a] [b] [c] [d] 8. [a] [b] [c] [d] 13. [a] [b] [c] [d] 4. [a] [b] [c] [d] 9. [a] [b] [c] [d] 14. [a] [b] [c] [d] 5. [a] [b] [c] [d] 10. [a] [b] [c] [d] 15. [a] [b] [c] [d] I am enclosing $5 for this month s quiz made payable to: Ohio Pharmacists Association. 1. Rate this lesson: (Ecellent) (Poor) 2. Did it meet each of its objectives? yes no If no, list any unmet 3. Was the content balanced and without commercial bias? yes no 4. Did the program meet your educational/practice needs? yes no 5. How long did it take you to read this lesson and complete the quiz? 6. Comments/future topics welcome. Please print. Program H01-P 0.15 CEU Name Address City, State, Zip NABP e-profile ID* *Obtain NABP e-profile number at Birthdate (MMDD) Return quiz and payment (check or money order) to Correspondence Course, OPA, 2674 Federated Blvd, Columbus, OH The IRIS trial established which of the following drugs as front-line therapy for CML? a. Dasatinib c. Nilotinib b. Imatinib d. Bosutinib 8. Bosutinib is approved for treating all of the following leukemias EXCEPT: a. acute phase Ph+ CML. c. accelerated phase Ph+ CML. b. chronic phase Ph+ CML. d. blast crisis Ph+ CML. 9. Which of the following is a contraindication to using Bosulif? a. Elevated liver enzymes b. Myelosuppression c. Hypersensitivity to bosutinib d. No contraindication listed 10. Patients receiving ponatinib should be counseled on the drug s potential for causing all the following EX- CEPT: a. bleeding. c. fluid retention. b. dementia. d. myelosuppression. 11. The recommended dose for ponatinib is: a. 5 mg once daily. c. 45 mg once daily. b. 25 mg twice daily. d. 75 mg twice daily. 12. A potential drug interaction with ponatinib is with: a. ketoconazole. c. St. John s Wort. b. verapamil. d. nafcillin. 13. The semisynthetic form of homoharringtonine is: a. imatinib. c. ponatinib. b. bosutinib. d. omacetaine. 14. The drug label that carries a Boed Warning advising about the risk of arterial thrombosis is: a. Gleevec. c. Iclusig. b. Bosulif. d. Synribo. 15. The method of administration for Synribo is: a. orally. c. intramuscularly. b. subcutaneously. d. intravenously. To receive CE credit, your quiz must be received no later than July 15, A passing grade of 80% must be attained. Quizzes are uploaded to the CPE Monitor. CE statements of credit will not be mailed. Send inquiries to opa@ohiopharmacists.org. july 2013

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including

More information

The CML Guide Information for Patients and Caregivers

The CML Guide Information for Patients and Caregivers The CML Guide Information for Patients and Caregivers LEUKEMIA LYMPHOMA CHRONIC MYELOGENOUS LEUKEMIA MYELOMA Printing of this publication made possible by a grant from A Message from John Walter President

More information

CML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More

CML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More A Patient s Guide to CML Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More cure C a n c e r U p d at e s, R e s e a r c h & E d u c at i o n Based on science,

More information

Medication Guide TASIGNA (ta-sig-na) (nilotinib) Capsules

Medication Guide TASIGNA (ta-sig-na) (nilotinib) Capsules Medication Guide TASIGNA (ta-sig-na) (nilotinib) Capsules Read this Medication Guide before you start taking Tasigna and each time you get a refill. There may be new information. This information does

More information

The CML Guide. Information for Patients and Caregivers. Chronic Myeloid Leukemia. Matthew, CML survivor. This publication was supported by

The CML Guide. Information for Patients and Caregivers. Chronic Myeloid Leukemia. Matthew, CML survivor. This publication was supported by The CML Guide Information for Patients and Caregivers Chronic Myeloid Leukemia Matthew, CML survivor This publication was supported by Revised 2014 A Message from Louis J. DeGennaro, PhD President and

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

Patient Medication Guide Brochure

Patient Medication Guide Brochure Patient Medication Guide Brochure 1 MEDICATION GUIDE TASIGNA (ta-sig-na) (nilotinib) Capsules Read this Medication Guide before you start taking TASIGNA and each time you get a refill. There may be new

More information

BRIEFING BOOK ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING NDA 22-374. (omacetaxine mepesuccinate)

BRIEFING BOOK ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING NDA 22-374. (omacetaxine mepesuccinate) BRIEFING BOOK ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING NDA 22-374 OMAPRO (omacetaxine mepesuccinate) ChemGenex Pharmaceuticals, Inc. 3715 Haven Avenue, Suite 100 Menlo Park, CA 94025 AVAILABLE FOR PUBLIC

More information

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods

More information

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014 ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the

More information

NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia

NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia S-1 NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia Susan O Brien, MD; Ellin Berman, MD; Joseph O. Moore, MD; Javier

More information

CHRONIC MYELOGENOUS LEUKEMIA

CHRONIC MYELOGENOUS LEUKEMIA CHRONIC MYELOGENOUS LEUKEMIA Executive Summary We propose the inclusion of treatment options for chronic myelogenous leukemia (CML), in the category of anti-neoplastic agents, including imatinib, nilotinib,

More information

Acute Myeloid Leukemia

Acute Myeloid Leukemia Acute Myeloid Leukemia Introduction Leukemia is cancer of the white blood cells. The increased number of these cells leads to overcrowding of healthy blood cells. As a result, the healthy cells are not

More information

Leukemias and Lymphomas: A primer

Leukemias and Lymphomas: A primer Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes

More information

Treatment Recommendations for People Living with CML

Treatment Recommendations for People Living with CML Treatment Recommendations for People Living with CML Foreword by CML Workgroup Chronic myeloid leukaemia (CML) is a disease of the blood and bone marrow that results when there is a cancerous transformation

More information

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Update in Hematology Oncology Targeted Therapies. Mark Holguin Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning

More information

GRANIX (tbo-filgrastim)

GRANIX (tbo-filgrastim) RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil

More information

CML Drugs and their Availability in the UK. Jane Apperley

CML Drugs and their Availability in the UK. Jane Apperley CML Drugs and their Availability in the UK Jane Apperley Drugs used in the treatment of CML Traditional chemotherapy Busulphan Hydoxycarbamide Interferon-alpha Omacetaxine Tyrosine kinase inhibitors Imatinib

More information

Summary of the risk management plan (RMP) for Cerdelga (eliglustat)

Summary of the risk management plan (RMP) for Cerdelga (eliglustat) EMA/743948/2014 Summary of the risk management plan (RMP) for Cerdelga (eliglustat) This is a summary of the risk management plan (RMP) for Cerdelga, which details the measures to be taken in order to

More information

Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2

Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2 Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2 Leukaemia: Description A group of malignant disorders affecting: White blood cells (lymphocytes or leucocytes) Bone

More information

Answering your questions on Chronic Myeloid Leukaemia (CML)

Answering your questions on Chronic Myeloid Leukaemia (CML) Answering your questions on Chronic Myeloid Leukaemia (CML) Your guide to understanding CML and Glivec (imatinib) treatment The information in this booklet is designed to help you understand chronic myeloid

More information

CAS Chemistry Research Report Delivering the latest trends in global chemistry research

CAS Chemistry Research Report Delivering the latest trends in global chemistry research Delivering the latest trends in global chemistry research Human Genome Discoveries Spur Growth of Cancer Treatments www.cas.org Strength of the Human Genome Project and Targeted Drugs In, President Clinton

More information

ACUTE MYELOID LEUKEMIA (AML),

ACUTE MYELOID LEUKEMIA (AML), 1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly

More information

Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets

Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets Read this Patient Information carefully before you start taking VYTORIN and each time you get a refill. There may be new information.

More information

5.07.09. Aubagio. Aubagio (teriflunomide) Description

5.07.09. Aubagio. Aubagio (teriflunomide) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)

More information

An Introduction to the Improved FDA Prescription Drug Labeling

An Introduction to the Improved FDA Prescription Drug Labeling An Introduction to the Improved FDA Prescription Drug Labeling 1 Introduction Mary E. Kremzner, Pharm.D. CDR, U.S. Public Health Service Deputy Director, Division of Drug Information Center for Drug Evaluation

More information

DVT/PE Management with Rivaroxaban (Xarelto)

DVT/PE Management with Rivaroxaban (Xarelto) DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular

More information

IMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products

IMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products Dear Healthcare Provider: Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) has been mandated by the FDA (Food and Drug Administration) due to postmarketing reports showing that exposure to

More information

Cytogenetics for the Rest of Us: A Primer

Cytogenetics for the Rest of Us: A Primer Cytogenetics for the Rest of Us: A Primer James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center Diane Maia, M.D. Pathologist, Bon Secours Hampton Roads Case #1 78 y.o. lady seen

More information

TAKING YOUR CML TREATMENT IN ANOTHER DIRECTION

TAKING YOUR CML TREATMENT IN ANOTHER DIRECTION APPROVED FOR AT-HOME USE FOR ADULTS WITH CHRONIC OR ACCELERATED PHASE CML FOLLOWING 2 OR MORE TKI FAILURES TAKING YOUR CML TREATMENT IN ANOTHER DIRECTION SYNRIBO (omacetaxine mepesuccinate) for injection,

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT

More information

NEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)

NEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with

More information

Keeping Track of Your Ph+ CML Treatment

Keeping Track of Your Ph+ CML Treatment Keeping Track of Your Ph+ CML Treatment A useful tool to learn how to set goals and track progress. Please see Important Safety Information for GLEEVEC (imatinib mesylate) and TASIGNA (nilotinib) on pages

More information

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Indication: In combination with docetaxel in locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma

More information

Creation of a Chronic Myeloid Leukemia Retrospective Outcomes Research Registry

Creation of a Chronic Myeloid Leukemia Retrospective Outcomes Research Registry Creation of a Chronic Myeloid Leukemia Retrospective Outcomes Research Registry David Stenehjem, Pharm.D. Research Assistant Professor Department of Pharmacotherapy Clinical Hematology/Oncology Pharmacist

More information

The Treatment of Leukemia

The Treatment of Leukemia The Treatment of Leukemia Guest Expert: Peter, MD Associate Professor of Hematology Director, Yale Cancer Center Leukemia Program www.wnpr.org www.yalecancercenter.org Hi, I am Bruce Barber and welcome

More information

Other treatments for chronic myeloid leukaemia

Other treatments for chronic myeloid leukaemia Other treatments for chronic myeloid leukaemia This information is an extract from the booklet Understanding chronic myeloid leukaemia. You may find the full booklet helpful. We can send you a copy free

More information

nilotinib 150mg hard capsules (Tasigna ) SMC No. (709/11) Novartis Pharmaceuticals UK Ltd

nilotinib 150mg hard capsules (Tasigna ) SMC No. (709/11) Novartis Pharmaceuticals UK Ltd nilotinib 150mg hard capsules (Tasigna ) SMC No. (709/11) Novartis Pharmaceuticals UK Ltd 08 July 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises

More information

Acute myeloid leukaemia (AML) in children

Acute myeloid leukaemia (AML) in children 1 61.02 Acute myeloid leukaemia (AML) in children AML can affect children of any age, and girls and boys are equally affected. Leukaemia Acute myeloid leukaemia (AML) FAB classification of AML Causes of

More information

A practical guide to understanding cancer. Understanding. chronic. myeloid. leukaemia

A practical guide to understanding cancer. Understanding. chronic. myeloid. leukaemia A practical guide to understanding cancer Understanding chronic myeloid leukaemia Contents 1 Contents About this booklet 3 1 The blood and chronic myeloid leukaemia 5 2 Diagnosing chronic myeloid leukaemia

More information

MEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate

MEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate MEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate Read this Medication Guide before you start receiving mitoxantrone and each time you receive mitoxantrone. There may be new information.

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers

More information

in silico hematology

in silico hematology in silico hematology Application of mathematical modeling to predict the outcome of leukemia treatment by Ingmar Glauche and Ingo Röder Chronic Myeloid Leukemia (CML) accounts for about 20 % of all leukemias

More information

Liver Disease & Hepatitis Program Providers: Brian McMahon, MD, Steve Livingston, MD, Lisa Townshend, ANP. Primary Care Provider:

Liver Disease & Hepatitis Program Providers: Brian McMahon, MD, Steve Livingston, MD, Lisa Townshend, ANP. Primary Care Provider: Liver Disease & Hepatitis Program Providers: Brian McMahon, MD, Steve Livingston, MD, Lisa Townshend, ANP Primary Care Provider: If you are considering hepatitis C treatment, please read this treatment

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information

Package leaflet: Information for the patient. Iclusig 45 mg film-coated tablets. Ponatinib

Package leaflet: Information for the patient. Iclusig 45 mg film-coated tablets. Ponatinib Package leaflet: Information for the patient Iclusig 15 mg film-coated tablets Iclusig 45 mg film-coated tablets Ponatinib This medicine is subject to additional monitoring. This will allow quick identification

More information

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing

More information

Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust.

Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust. Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust. This Patient Group Direction (PGD) has been written

More information

UNDERSTANDING MULTIPLE MYELOMA AND YOUR TREATMENT. It is not known if REVLIMID is safe and effective in children under 18 years of age My Moment

UNDERSTANDING MULTIPLE MYELOMA AND YOUR TREATMENT. It is not known if REVLIMID is safe and effective in children under 18 years of age My Moment TREATMENT OVERVIEW REVLIMID (lenalidomide) is used with dexamethasone to treat patients with multiple myeloma (MM) REVLIMID should not be used to treat people who have chronic lymphocytic leukemia (CLL)

More information

Leukemia-Chronic Myeloid (Myelogenous) Overview

Leukemia-Chronic Myeloid (Myelogenous) Overview Leukemia-Chronic Myeloid (Myelogenous) Overview This overview is based on the more detailed information in our document, Leukemia- Chronic Myeloid. You can get this document and other information by calling

More information

Canine Lymphoma Frequently Asked Questions by Pet Owners

Canine Lymphoma Frequently Asked Questions by Pet Owners Canine Lymphoma Frequently Asked Questions by Pet Owners What is lymphoma? The term lymphoma describes a diverse group of cancers in dogs that are derived from white blood cells called lymphocytes. Lymphocytes

More information

Drug/Drug and Drug/Food Interactions with Target-Specific Oral Anticoagulants

Drug/Drug and Drug/Food Interactions with Target-Specific Oral Anticoagulants Drug/Drug and Drug/Food Interactions with Target-Specific Oral Anticoagulants Sara R. Vazquez, PharmD, BCPS, CACP Clinical Pharmacist University of Utah Health Care Thrombosis Service Nothing to disclose

More information

**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011

**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011 Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both

More information

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15 Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

TSOAC Initiation Checklist

TSOAC Initiation Checklist Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.

More information

Summary of the risk management plan (RMP) for Ofev (nintedanib)

Summary of the risk management plan (RMP) for Ofev (nintedanib) EMA/738120/2014 Summary of the risk management plan (RMP) for Ofev (nintedanib) This is a summary of the risk management plan (RMP) for Ofev, which details the measures to be taken in order to ensure that

More information

What is chronic myeloid leukaemia?

What is chronic myeloid leukaemia? Chronic Myeloid Leukaemia What is chronic myeloid leukaemia? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines CHRONIC

More information

Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).

Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011). Page 1 of 10 ANALYTE NAME AND STRUCTURE TERIFLUNOMIDE Teriflunomide TRADE NAME Aubagio CATEGORY Antimetabolite TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND sclerosis. The

More information

Living with multiple myeloma A guide for patients and caregivers

Living with multiple myeloma A guide for patients and caregivers Living with multiple myeloma A guide for patients and caregivers VELCADE (bortezomib) is approved for the treatment of patients with multiple myeloma (a cancer of the plasma cells). Before you receive

More information

More information for patients and caregivers can be accessed at http://www.xarelto-us.com/.

More information for patients and caregivers can be accessed at http://www.xarelto-us.com/. Janssen Research & Development Submits Application to U.S. FDA for XARELTO (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome RARITAN, DECEMBER 29, 2011 -

More information

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application

More information

QUESTIONS TO ASK MY DOCTOR

QUESTIONS TO ASK MY DOCTOR Be a part of the treatment decision by asking questions QUESTIONS TO ASK MY DOCTOR FOR PATIENTS WITH ADVANCED STOMACH OR GASTROESOPHAGEAL JUNCTION (GEJ) CANCER CYRAMZA (ramucirumab) is used alone or in

More information

Hospital Outpatient Coding and Billing Information Sheet for Neulasta and NEUPOGEN

Hospital Outpatient Coding and Billing Information Sheet for Neulasta and NEUPOGEN Hospital Outpatient Coding and Billing Information Sheet for Neulasta and Neulasta Delivery Kit Neulasta Prefilled Syringe For assistance contact 1-844-MYNEULASTA (1-844-696-3852) or visit www.amgenassistonline.com

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Multiple Myeloma. This reference summary will help you understand multiple myeloma and its treatment options.

Multiple Myeloma. This reference summary will help you understand multiple myeloma and its treatment options. Multiple Myeloma Introduction Multiple myeloma is a type of cancer that affects white blood cells. Each year, thousands of people find out that they have multiple myeloma. This reference summary will help

More information

MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol)

MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol) MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol) 1. Hepatotoxicity: In Active TB Disease a. Background: 1. Among the 4 standard anti-tb drugs,

More information

Study of Imatinib Treatment Patterns and Outcomes Among US Veteran Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Study of Imatinib Treatment Patterns and Outcomes Among US Veteran Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Health Care Delivery Original Contribution Study of Imatinib Treatment Patterns and Outcomes Among US Veteran Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia By Nancy Vander Velde,

More information

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational

More information

CML TREATMENT GUIDELINES

CML TREATMENT GUIDELINES CML TREATMENT GUIDELINES VERSION 2015 INITIAL INVESTIGATION Propose enrolment in the CML Registry of the CML-MPN Quebec Research Group (GQR LMC-NMP) Medical history: Question for vascular disease (neurologic,

More information

La Targeted Therapy e l appropriatezza terapeutica

La Targeted Therapy e l appropriatezza terapeutica TRAINING REGIONALE PER FARMACISTI OSPEDALIERI SU LEUCEMIA MIELOIDE CRONICA (LMC), NUOVE TECNOLOGIE ED APPROCCI Roma, 16 Novembre 2015 La Targeted Therapy e l appropriatezza terapeutica Cinzia Dello Russo

More information

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour. Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,

More information

Introduction. Background

Introduction. Background INFORMATION DRIVES SOUND ANALYSIS, INSIGHT PHARMACY BENEFIT ADVISORY Introduction According to the Centers for Disease Control and Prevention (CDC), the rate of new hepatitis C virus (HCV) infections in

More information

Corporate Medical Policy Genetic Testing for Fanconi Anemia

Corporate Medical Policy Genetic Testing for Fanconi Anemia Corporate Medical Policy Genetic Testing for Fanconi Anemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_fanconi_anemia 03/2015 3/2016 3/2017 3/2016 Description

More information

Synopsis of Causation. Chronic Myeloid Leukaemia

Synopsis of Causation. Chronic Myeloid Leukaemia Ministry of Defence Synopsis of Causation Chronic Myeloid Leukaemia Author: Dr M A Vickers, University of Aberdeen, Aberdeen Validator: Professor John Goldman, Hammersmith Hospital, London September 2008

More information

My Sister s s Keeper. Science Background Talk

My Sister s s Keeper. Science Background Talk My Sister s s Keeper Science Background Talk Outline Acute promyelocytic leukemia (APL) APL Treatment Savior Siblings In vitro fertilization (IVF) Pre-implantation Genetic Diagnosis (PGD) Risks of donating

More information

MEDICATION GUIDE POMALYST (POM-uh-list) (pomalidomide) capsules. What is the most important information I should know about POMALYST?

MEDICATION GUIDE POMALYST (POM-uh-list) (pomalidomide) capsules. What is the most important information I should know about POMALYST? MEDICATION GUIDE POMALYST (POM-uh-list) (pomalidomide) capsules What is the most important information I should know about POMALYST? Before you begin taking POMALYST, you must read and agree to all of

More information

Patient Information Leaflet Drug interaction with ED drug treatments

Patient Information Leaflet Drug interaction with ED drug treatments Patient Information Leaflet Drug interaction with ED drug treatments This document is intended for information purposes only and should be used in conjunction with the advice and further details to be

More information

Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections

Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.

More information

Summary of the risk management plan (RMP) for Accofil (filgrastim)

Summary of the risk management plan (RMP) for Accofil (filgrastim) EMA/475472/2014 Summary of the risk management plan (RMP) for Accofil (filgrastim) This is a summary of the risk management plan (RMP) for Accofil, which details the measures to be taken in order to ensure

More information

Below, this letter outlines [patient name] s medical history, prognosis, and treatment rationale.

Below, this letter outlines [patient name] s medical history, prognosis, and treatment rationale. [Date] [Name of Contact] [Title] [Name of Health Insurance Company] [Address] [City, State, Zip Code] Insured: [Patient Name] Policy Number: [Number] Group Number: [Number] Diagnosis: [Diagnosis and ICD-9-CM

More information

Chronic Myeloid Leukaemia (CML)

Chronic Myeloid Leukaemia (CML) Chronic Myeloid Leukaemia (CML) A guide for patients and families 1800 620 420 leukaemia.org.au Notes Contents Acknowledgements 4 Introduction 5 The Leukaemia Foundation 6 What is chronic myeloid leukaemia

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions

More information

Controversies in the management of patients with PMF 0/1

Controversies in the management of patients with PMF 0/1 State of the art treatments of patients with MPNs Turracher Höhe 2010 Controversies in the management of patients with PMF 0/1 Heinz Gisslinger Medical University of Vienna Divison for Hematology, Vienna

More information

A Science Writer s Guide to Multiple Myeloma

A Science Writer s Guide to Multiple Myeloma A Science Writer s Guide to Multiple Myeloma 1 A Science Writer s Guide to Multiple Myeloma A Science Writer s Guide to Multiple Myeloma PREFACE Blood cancers and related disorders a serious health risk

More information

Daclatasvir (Daklinza)

Daclatasvir (Daklinza) FACTSHEET Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION A Notice of Compliance with Conditions (NOC/c) is a type of approval to sell a drug in Canada. IMBRUVICA is used to

More information

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart

More information

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)

More information

Acute myeloid leukemia (AML)

Acute myeloid leukemia (AML) Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants

More information

MEDICATION GUIDE. PROCRIT (PRO KRIT) (epoetin alfa)

MEDICATION GUIDE. PROCRIT (PRO KRIT) (epoetin alfa) MEDICATION GUIDE PROCRIT (PROKRIT) (epoetin alfa) Read this Medication Guide: before you start PROCRIT. if you are told by your healthcare provider that there is new information about PROCRIT. if you are

More information

NCCP Chemotherapy Protocol. Afatinib Monotherapy

NCCP Chemotherapy Protocol. Afatinib Monotherapy Afatinib Monotherapy INDICATIONS FOR USE: INDICATION Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

More information

Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU

Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU FOR MS RELAPSES Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU As a person with multiple sclerosis (MS), you know firsthand the profound impact MS relapses can have on your

More information

PATIENT MEDICATION INFORMATION

PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr CYRAMZA ramucirumab Read this carefully before you receive CYRAMZA (pronounced "si ram - ze"). This leaflet is a

More information

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and

More information

LYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis

LYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis LYMPHOMA IN DOGS Lymphoma is a relatively common cancer in dogs. It is a cancer of lymphocytes (a type of white blood cell) and lymphoid tissues. Lymphoid tissue is normally present in many places in the

More information

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs? Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning A Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning Drugs to Prevent Abnormal Blood

More information

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections

More information